BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 28967901)

  • 1. Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy.
    Mett V; Komarova EA; Greene K; Bespalov I; Brackett C; Gillard B; Gleiberman AS; Toshkov IA; Aygün-Sunar S; Johnson C; Karasik E; Bapardekar-Nair M; Kurnasov OV; Osterman AL; Stanhope-Baker PS; Morrison C; Moser MT; Foster BA; Gudkov AV
    Oncogene; 2018 Jan; 37(4):439-449. PubMed ID: 28967901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-in-human study of anticancer immunotherapy drug candidate mobilan: safety, pharmacokinetics and pharmacodynamics in prostate cancer patients.
    Eremina NV; Kazey VI; Mishugin SV; Leonenkov RV; Pushkar DY; Mett VL; Gudkov AV
    Oncotarget; 2020 Apr; 11(14):1273-1288. PubMed ID: 32292576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flagellin enhances tumor-specific CD8⁺ T cell immune responses through TLR5 stimulation in a therapeutic cancer vaccine model.
    Nguyen CT; Hong SH; Sin JI; Vu HV; Jeong K; Cho KO; Uematsu S; Akira S; Lee SE; Rhee JH
    Vaccine; 2013 Aug; 31(37):3879-87. PubMed ID: 23831323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist.
    Burdelya LG; Brackett CM; Kojouharov B; Gitlin II; Leonova KI; Gleiberman AS; Aygun-Sunar S; Veith J; Johnson C; Haderski GJ; Stanhope-Baker P; Allamaneni S; Skitzki J; Zeng M; Martsen E; Medvedev A; Scheblyakov D; Artemicheva NM; Logunov DY; Gintsburg AL; Naroditsky BS; Makarov SS; Gudkov AV
    Proc Natl Acad Sci U S A; 2013 May; 110(20):E1857-66. PubMed ID: 23630282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism.
    Yang H; Brackett CM; Morales-Tirado VM; Li Z; Zhang Q; Wilson MW; Benjamin C; Harris W; Waller EK; Gudkov AV; Burdelya LG; Grossniklaus HE
    Oncotarget; 2016 Jan; 7(3):2936-50. PubMed ID: 26655090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axis.
    Brackett CM; Kojouharov B; Veith J; Greene KF; Burdelya LG; Gollnick SO; Abrams SI; Gudkov AV
    Proc Natl Acad Sci U S A; 2016 Feb; 113(7):E874-83. PubMed ID: 26831100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic cell based PSMA immunotherapy for prostate cancer using a CD40-targeted adenovirus vector.
    Williams BJ; Bhatia S; Adams LK; Boling S; Carroll JL; Li XL; Rogers DL; Korokhov N; Kovesdi I; Pereboev AV; Curiel DT; Mathis JM
    PLoS One; 2012; 7(10):e46981. PubMed ID: 23056548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-step enhanced cancer immunotherapy with engineered
    Zheng JH; Nguyen VH; Jiang SN; Park SH; Tan W; Hong SH; Shin MG; Chung IJ; Hong Y; Bom HS; Choy HE; Lee SE; Rhee JH; Min JJ
    Sci Transl Med; 2017 Feb; 9(376):. PubMed ID: 28179508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects.
    Haderski GJ; Kandar BM; Brackett CM; Toshkov IM; Johnson CP; Paszkiewicz GM; Natarajan V; Gleiberman AS; Gudkov AV; Burdelya LG
    PLoS One; 2020; 15(2):e0227940. PubMed ID: 32027657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attenuation of the glucocorticoid response during Ad5IL-12 adenovirus vector treatment enhances natural killer cell-mediated killing of MHC class I-negative LNCaP prostate tumors.
    Raja Gabaglia C; Diaz de Durana Y; Graham FL; Gauldie J; Sercarz EE; Braciak TA
    Cancer Res; 2007 Mar; 67(5):2290-7. PubMed ID: 17332360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-γ+IL-17+ polyfunctional T cells that mediate rejection of murine tumors.
    Marshall NA; Galvin KC; Corcoran AM; Boon L; Higgs R; Mills KH
    Cancer Res; 2012 Feb; 72(3):581-91. PubMed ID: 22158905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Versatile prostate cancer treatment with inducible caspase and interleukin-12.
    Nikitina EY; Desai SA; Zhao X; Song W; Luo AZ; Gangula RD; Slawin KM; Spencer DM
    Cancer Res; 2005 May; 65(10):4309-19. PubMed ID: 15899823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A flagellin-derived toll-like receptor 5 agonist stimulates cytotoxic lymphocyte-mediated tumor immunity.
    Leigh ND; Bian G; Ding X; Liu H; Aygun-Sunar S; Burdelya LG; Gudkov AV; Cao X
    PLoS One; 2014; 9(1):e85587. PubMed ID: 24454895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer.
    Rhee SH; Im E; Pothoulakis C
    Gastroenterology; 2008 Aug; 135(2):518-28. PubMed ID: 18538140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C; Sanda MG
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flagellin acting via TLR5 is the major activator of key signaling pathways leading to NF-kappa B and proinflammatory gene program activation in intestinal epithelial cells.
    Tallant T; Deb A; Kar N; Lupica J; de Veer MJ; DiDonato JA
    BMC Microbiol; 2004 Aug; 4():33. PubMed ID: 15324458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pterostilbene, a novel natural plant conduct, inhibits high fat-induced atherosclerosis inflammation via NF-κB signaling pathway in Toll-like receptor 5 (TLR5) deficient mice.
    Zhang Y; Zhang Y
    Biomed Pharmacother; 2016 Jul; 81():345-355. PubMed ID: 27261612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multifunctional chimeric chaperone serves as a novel immune modulator inducing therapeutic antitumor immunity.
    Yu X; Guo C; Yi H; Qian J; Fisher PB; Subjeck JR; Wang XY
    Cancer Res; 2013 Apr; 73(7):2093-103. PubMed ID: 23333935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional characterization of chicken TLR5 reveals species-specific recognition of flagellin.
    Keestra AM; de Zoete MR; van Aubel RA; van Putten JP
    Mol Immunol; 2008 Mar; 45(5):1298-307. PubMed ID: 17964652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.